Last reviewed · How we verify

Malignant tumor of lung — Treatment Landscape & Competitive Intelligence

Malignant tumor of lung (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Malignant tumor of lung, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Laserphyrin TALAPORFIN Meiji Seika Pharm talaporfin 2015-01-01
Liposomal Doxorubicin liposomal-doxorubicin Pfizer doxorubicin 72 kDa type IV collagenase 1974-01-01
Doxorubicin Hydrochloride doxorubicin Pfizer Anthracycline Topoisomerase Inhibitor Aurora kinase A 1974-01-01
Trexall methotrexate Generic (originally Lederle Laboratories) Antifolate, DMARD Canalicular multispecific organic anion transporter 1, High mobility group protein B1, Multidrug resistance-associated protein 4 1953-12-07
Valchlor MECHLORETHAMINE Recordati Alkylating Drug [EPC] 1949-01-01
Adriamycin Adriamycin Johann Wolfgang Goethe University Hospital Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 6, 72 kDa type IV collagenase
Methotrexat Methotrexat Biocad Canalicular multispecific organic anion transporter 1, High mobility group protein B1, Multidrug resistance-associated protein 4
Hydroxydaunomycin Hydroxydaunomycin Weill Medical College of Cornell University Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 6, 72 kDa type IV collagenase
Hydroxydaunorubicin Hydroxydaunorubicin University of Colorado, Denver Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 6, 72 kDa type IV collagenase
adriacin adriacin Chipscreen Biosciences, Ltd. Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 6, 72 kDa type IV collagenase

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Pfizer · 2 drugs in Malignant tumor of lung
  2. · 2 drugs in Malignant tumor of lung
  3. Chipscreen Biosciences, Ltd. · 1 drug in Malignant tumor of lung
  4. Generic (originally Lederle Laboratories) · 1 drug in Malignant tumor of lung
  5. Johann Wolfgang Goethe University Hospital · 1 drug in Malignant tumor of lung
  6. Meiji Seika Pharm · 1 drug in Malignant tumor of lung
  7. Recordati · 1 drug in Malignant tumor of lung
  8. The Lymphoma Academic Research Organisation · 1 drug in Malignant tumor of lung
  9. University of Colorado, Denver · 1 drug in Malignant tumor of lung
  10. Weill Medical College of Cornell University · 1 drug in Malignant tumor of lung
  11. Biocad · 1 drug in Malignant tumor of lung

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Malignant tumor of lung:

Cite this brief

Drug Landscape (2026). Malignant tumor of lung — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/malignant-tumor-of-lung. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing